Clinical Trial Update: Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of fingolimod (FTY720) in de novo adult renal transplant recipients has completed. The sponsor is Novartis Phar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 3 | Status: COMPLETED